Barinthus Biotherapeutics (NASDAQ:BRNS) Announces Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) released its quarterly earnings data on Friday. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09, Zacks reports.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock traded down $0.12 during trading hours on Friday, hitting $1.07. The company’s stock had a trading volume of 116,960 shares, compared to its average volume of 43,794. The company has a market cap of $43.57 million, a PE ratio of -0.62 and a beta of -0.70. The business has a 50 day moving average price of $1.26 and a two-hundred day moving average price of $1.15. Barinthus Biotherapeutics has a 12-month low of $0.64 and a 12-month high of $2.92.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. raised its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 25.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Barinthus Biotherapeutics in a report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $3.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.